

# Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Zhigang Wei · Xin Ye · Xia Yang · Aimin Zheng ·  
Guanghui Huang · Wenhong Li · Xiang Ni ·  
Jiao Wang · Xiaoying Han

Received: 15 August 2013 / Accepted: 21 March 2014 / Published online: 9 May 2014

© Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2014

## Abstract

**Purpose** To verify whether microwave ablation (MWA) used as a local control treatment had an improved outcome regarding advanced non-small cell lung cancer (NSCLC) when combined with chemotherapy.

**Methods** Thirty-nine patients with histologically verified advanced NSCLC and at least one measurable site other than the ablative sites were enrolled. Primary tumors underwent MWA followed by platinum-based doublet chemotherapy. Modified response evaluation criteria in solid tumors (mRECIST) and RECIST were used to evaluate therapeutic response. Complications were assessed using the National Cancer Institute Common Toxicity Criteria (version 3.0).

**Results** MWA was administered to 39 tumors in 39 patients. The mean and median diameters of the primary tumor were 3.84 cm and 3.30 cm, respectively, with a range of 1.00–9.00 cm. Thirty-three (84.6 %) patients achieved a partial response. No correlation was found between MWA efficacy and clinicopathologic characteristics. For chemotherapy, 11 patients (28.2 %) achieved a partial response, 18 (46.2 %) showed stable disease, and 10 (25.6 %) had progressive disease. The overall objective response rate and disease control rate were 28.2 and 74.4 %, respectively. The median progression-free survival time was 8.7 months (95 % CI 5.5–11.9). The median overall survival time was 21.3 months (95 % CI 17.0–25.4). Complications were observed in 22 (56.4 %) patients, and grade 3 adverse events were observed in 3 (7.9 %) patients.

**Conclusions** Patients with advanced NSCLC could benefit from MWA in combination with chemotherapy. Complications associated with MWA were common but tolerable.

**Keywords** Non-small cell lung cancer · Microwave ablation · Chemotherapy

---

Z. Wei · X. Ye (✉) · X. Yang · A. Zheng · G. Huang ·  
W. Li · X. Ni · J. Wang · X. Han  
Department of Oncology, Shandong Provincial Hospital  
Affiliated to Shandong University, 324 Jingwuweiqi Road,  
Jinan 250021, Shandong, China  
e-mail: yexintaian@aliyun.com

Z. Wei  
e-mail: weizhigang321321@163.com

X. Yang  
e-mail: yangxjinan@163.com

A. Zheng  
e-mail: am-zheng@163.com

G. Huang  
e-mail: hgh3612@163.com

W. Li  
e-mail: wenghong\_li@163.com

X. Ni  
e-mail: asuka2521@hotmail.com

X. Han  
e-mail: mylittlecarol@sina.com

## Introduction

Lung cancer remains the leading cause of cancer-related mortality worldwide [1]. Non-small cell lung cancer (NSCLC), comprised of adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, accounts for nearly 80–85 % of this disease. Although diagnosis and treatment has improved dramatically, the overall 5-year survival rate is still 15 % [2]. This dismal prognosis is mainly because nearly two-thirds of patients are diagnosed at an advanced stage, losing the opportunity for radical surgery.

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and anaplastic lymphoma kinase (ALK) inhibitor (crizotinib) have dramatically improved the response and progression-free survival (PFS) times of NSCLC patients harboring EGFR-sensitive mutations [3–7] and the echinoderm microtubule-associated protein like-4 (EML4)-ALK fusion gene [8, 9]. However, for patients without these sensitive gene exchanges chemotherapy, particularly platinum-based doublet chemotherapy, is still the mainstay of treatment.

Microwave ablation (MWA) as a local tumor control treatment has been applied recently. This modality involves the use of electromagnetic waves to produce tissue-heating effects. The microwave energy spectrum has a very high frequency between 300 MHz and 300 GHz, which results in a large zone of active heating [10]. Once the temperature of the ablation zone reaches 65–160 °C, coagulation necrosis will occur. Several studies have demonstrated that MWA could be an alternative approach for early-stage NSCLC patients who are high-risk for surgery [11–13].

However, no reports have explored whether MWA treatment of primary tumors, as an adjuvant to platinum-based doublet chemotherapy, could improve the response and survival of advanced NSCLC patients. We conducted this retrospective study with the objective of assessing the efficacy and safety of MWA in combination with chemotherapy for the treatment of advanced NSCLC.

## Materials and Methods

### Inclusion and Exclusion Criteria

Patients with histologically verified stage IIIB or IV NSCLC were included in this study. They all received microwave ablation in combination with platinum-based doublet chemotherapy and had at least one measurable site besides the ablative sites. Other inclusion criteria were as follows: age  $\geq 18$  years; an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; and adequate hepatic, renal, and hematologic function. Patients with the following characteristics were excluded: a life expectancy of 3 months; symptomatic brain metastases; the occurrence of other malignant tumors within the past 5 years; and prior percutaneous thermal ablation or chemotherapy. The study was approved by the Research Ethics Committee of the Institute of Shandong Provincial Hospital affiliated to Shandong University. Written, informed consent was obtained from all patients.

### Clinical Data

From February 2010 to January 2013, 69 lung cancer patients who received MWA combined with doublet

**Table 1** Clinicopathologic characteristics of the 39 NSCLC patients

| Characteristics    | Number of patients | Percentage |
|--------------------|--------------------|------------|
| Gender             |                    |            |
| Male               | 22                 | 56.4       |
| Female             | 17                 | 43.6       |
| Average age (year) | 57 (35–88)         |            |
| Smoking history    |                    |            |
| Smokers            | 19                 | 48.7       |
| Nonsmokers         | 20                 | 51.3       |
| Pathology          |                    |            |
| ADC                | 27                 | 69.2       |
| Non-ADC            | 12                 | 30.8       |
| Stage              |                    |            |
| IV                 | 35                 | 89.7       |
| IIIB               | 4                  | 10.3       |
| ECOG               |                    |            |
| 0–1                | 36                 | 92.3       |
| 2                  | 3                  | 7.7        |
| Weight loss        |                    |            |
| $\geq 5\%$         | 8                  | 20.5       |
| $< 5\%$            | 31                 | 79.5       |
| Tumor size (cm)    |                    |            |
| $\geq 3$           | 21                 | 53.8       |
| $< 3$              | 18                 | 46.2       |

chemotherapy were screened. Thirty patients were excluded. Among them, 20 patients had stage I–II disease, 5 had received prior anticancer therapies, and 5 had small cell lung cancer. Of the 39 patients enrolled, 22 (56.4 %) were men with a mean age of 57 (range 35–88) years; 19 (48.7 %) were former or current smokers, 27 (69.2 %) had adenocarcinoma, 35 (89.7 %) had stage IV disease, 36 (92.3 %) had an ECOG of 0–1, 31 (79.5 %) had experienced weight loss  $\geq 5\%$ , 21 (53.8 %) had a tumor size  $\geq 3$  cm, and 7 had recurrence after radical surgery. A total of 39 lung nodular lesions from 39 patients were detected using CT. The baseline characteristics of the 39 enrolled patients are detailed in Table 1.

Among the 39 patients, primary tumors in the right lung were observed in 24 patients. The mean and median tumor diameters were 3.84 and 3.30 cm respectively, with a range of 1.00–9.00 cm. Twenty-eight patients had lymph node metastases and 35 had distant metastases. The lung, bone, pleural, and pericardium were the common metastatic sites. Table 2 details the characteristics of the disease.

### MWA Procedure

A GE-lightspeed 64 V spiral CT machine was used for the scanning of all patients. The MWA instrument used was a

**Table 2** Characteristics of the disease

| Characteristics             | Number of patients | Percentage |
|-----------------------------|--------------------|------------|
| Primary tumor sites         |                    |            |
| Right upper lobe            | 15                 | 38.5       |
| Right middle lobe           | 4                  | 10.2       |
| Right lower lobe            | 5                  | 12.8       |
| Left upper lobe             | 9                  | 23.1       |
| Left lower lobe             | 6                  | 15.4       |
| Primary tumor size          |                    |            |
| Median (cm)                 | 3.30               |            |
| Mean (cm)                   | 3.84               |            |
| Range (cm)                  | 1.00–9.00          |            |
| Lymph node metastases       |                    |            |
| Yes                         | 28                 | 71.8       |
| No                          | 11                 | 28.2       |
| Distant metastasis location |                    |            |
| Lung                        | 6                  | 15.4       |
| Liver                       | 4                  | 10.3       |
| Bone                        | 9                  | 23.1       |
| Brain                       | 3                  | 7.7        |
| Adrenal                     | 5                  | 12.8       |
| Pleura                      | 11                 | 28.2       |
| Pericardium                 | 6                  | 15.4       |
| Other sites                 | 4                  | 10.3       |
| Distant metastases          |                    |            |
| No                          | 4                  | 10.3       |
| One site                    | 17                 | 43.6       |
| Two or three sites          | 18                 | 46.2       |

MTC-3C (YZB 1408-2003. No: SFDA (III) 20073251059: Nanjing Qiya Medical Equipment Co., Jiangsu, China). The microwave emission frequency was  $2,450 \pm 50$  MHz, and output level adjustable continuous wave ranged between 0 and 100 W. The microwave antenna had an effective length of 100–180 mm and an outside diameter of 14–20 G, with a long tapered pointed end; a water circulation cooling system was used to reduce the surface temperature of the antenna. MWA with an output of 60–80 W has an ablative zone of nearly  $3.5 \times 3$  cm<sup>2</sup>. For tumors 3.5 cm, the ablation was conducted in several positions with an ablative needle. Local anesthesia and preemptive analgesia were used [14]. Preoperative localization was confirmed by observation of CT images and patient movement into different positions. After the achievement of satisfactory anesthesia, the MWA procedure was performed by cutting the skin at the punctured point, puncturing the ablation microwave antenna through the deeper layers of tissue to the nodular lesion; this was performed according to the preoperative-planned channel, with the puncture depth as the preoperative-planned “target-skin distance.” MWA could be performed after the cold

circulating pipes and circulating pumps had been connected to the MWA antenna and MWA machine with a cable. After this procedure, the microwave ablation antenna was extracted, local disinfection was performed, and a bandage was used to seal the wound. CT scan was performed immediately after MWA had taken place to observe the size, shape relation organs close to the nodular lesion, as well as to determine if there were any signs of pneumothorax, bleeding, or other problems. The proposed ablative margin was 0.5 cm.

### Chemotherapy

All patients were treated with MWA, followed by chemotherapy during the subsequent 7 days. The protocol was broadly in accordance with the sequence of radiofrequency ablation combined with chemotherapy used in the treatment of advanced NSCLC. The chemotherapy regimens included gemcitabine (1,250 mg/m<sup>2</sup>) on days 1 and 8, or docetaxel (75 mg/m<sup>2</sup>) on day 1, or pemetrexed (500 mg/m<sup>2</sup>) on day 1. Platinum-based doublet chemotherapies involved the combination of the former three anticancer drugs with cisplatin (75 mg/m<sup>2</sup>) on days 1 and 2 or carboplatin with an area under curve of 5 on day 1. All regimens were repeated every 3 weeks. Up to six cycles of chemotherapy were administered.

### Follow-up Schedule

At 48 h and 1, 3, 6, 9, and 12 months after MWA patients received a CT scan to assess their response to treatment and to identify adverse events; the CT scan taken after 1 month of MWA was used as the baseline scan for evaluation of the response to treatment. The assessment of response to chemotherapy was conducted every two cycles. For patients who completed the established regimens, follow-up was performed every 3 months.

### Clinical Evaluation

Change in the size of the primary tumor after treatment with MWA was used for the assessment of response. Measurable tumor sites other than the primary tumor site were used to assess the response to chemotherapy. The response to MWA was classified as a complete response, a partial response (PR), stable disease (SD), and progressive disease (PD) according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST; Table 3) [15, 16]. The response to chemotherapy was evaluated based on RECIST 1.1 [17]. Assessment of complications associated with MWA was in accordance with the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC3.0).

**Table 3** Modified RECIST criteria used to evaluate treatment response

| Response              | Size of CT mass   | Quality of CT mass  | PET                                 |
|-----------------------|---|---|-------------------------------------|
| Complete (any 2)      | Disappearance of the lesion or a presence of a scar 25 % of its original size | Cyst or cavity formation.<br>Low density of the entire lesion | SUV 2.5                             |
| Partial (any 1)       | Decrease of 30 % in LD of target lesion                                       | Central necrosis or central cavitation with liquid density    | Decreased SUV or area of FDG uptake |
| Stable lesion (any 1) | Decrease of 30 % in LD of target lesion                                       | Mass with solid appearance, no central necrosis or cavity     | Unchanged SUV or area of FDG uptake |
| Progression (any 2)   | Increase of 20 % in LD of target lesion                                       | Solid mass and invasion of adjacent structures                | Higher SUV                          |

Target lesions represent tumors treated with RFA

SUV standard uptake value for fluorodeoxyglucose F18 in the PET scan; LD largest diameter of target lesion; FDG fluorodeoxyglucose F18

### Statistical Analysis

The correlations between therapeutic response to MWA and clinicopathological characteristics were assessed using the  $\chi^2$  test. PFS was calculated from the date of diagnosis or recurrence after surgical resection to the date of progression or death. Overall survival (OS) was calculated from the time of diagnosis to the time of death or the last follow-up. Kaplan–Meier analysis was applied for the assessment of survival. All tests were two-sided, and  $p < 0.05$  was considered as being statistically significant. All analyses were performed using SPSS for Windows Version 17.0 (IBM, Chicago, IL).

## Results

### Response to MWA and Chemotherapy

All patients who were enrolled in the study received MWA at their primary tumor sites. A total of 39 percutaneous MWAs for 39 tumors were administrated in the 39 patients. Four (10.3 %) patients were treated with 60 W MWA, and 35 (89.7 %) with 70 W MWA. The median ablation time was 6 (range 4–11) min. Thirty-three (84.6 %) patients achieved a PR, and six (15.4 %) patients exhibited SD (Fig. 1). No correlation was found between the response to

MWA and the following clinicopathologic characteristics: gender ( $p = 0.0578$ ); smoking history ( $p = 0.946$ ); pathology ( $p = 0.883$ ); stage ( $p = 0.374$ ); ECOG PS ( $p = 0.177$ ); and weight loss ( $p = 0.796$ ). All patients were treated with platinum-based doublet chemotherapy post-MWA, with a median of four (range 2–6) cycles. Eleven patients (28.2 %) achieved a PR, 18 (46.2 %) showed SD, and 10 (25.6 %) had PD. The objective response rate (ORR) for the combined treatments was 28.2 % and the disease control rate (DCR) was 74.4 %.

### Survival


At the last follow-up on April 14, 2013, which represented a median follow-up time of 11.2 (range 2.5–29.2) months, 23 patients (59.0 %) exhibited tumor progression and 9 patients (23.1 %) had died. Among the patients with disease progression, 7 had progressed at ablative sites, 15 had developed metastases in lobes other than at the ablative sites or distant sites, and 1 had metastases at both the ablative site and a distant site. The median PFS time was 8.6 months (95 % CI 5.5–11.9) in patients treated with MWA in combination with chemotherapy (Fig. 2). The median OS time was 21.3 months (95 % CI 17–25.4; Fig. 3).

### Safety of MWA

Complications associated with MWA included pneumothorax, infection, pleural effusion, and hemothorax; these were observed in 12 (30.8 %), 7 (18.0 %), 7 (18.0 %), and 6 (15.3 %) patients, respectively. In total, 22 patients (56.4 %) suffered from adverse events. No adverse events related to mortality were observed. These adverse events were predominantly of grade 1 or 2 (19/22 [86.4 %]) with the exception of three (13.6 %) patients with grade 3 pneumothorax, which required chest tube intervention. Adverse events associated with the use of MWA were observed in 12 patients, 7 at 48 h post-MWA.

## Discussion

For advanced NSCLC, chemotherapy especially third-generation platinum-based doublet chemotherapy remains the standard treatment. However, only 30–40 % of patients benefit from treatment. Most patients exhibit tumor progression during the initial therapy, and even patients who achieve disease control will eventually progress. In NSCLC patients, the failure of chemotherapy is often the result of three major factors. The first is distant metastases, the second uncontrolled local sites, and the third is disruption of immune function. The former and the latter



**Fig. 1** A 68-year-old female with the diagnosis of left upper lobe adenocarcinoma at stage IIIb (T2N3M0). *1* A primary tumor with a diameter of 3.4 cm. *2* The positioning image before treatment. *3* Puncture of the ablative antenna into the tumor. *4* The image obtained immediately after MWA; ground glass opacity around the tumor and cavity in the core was observed. *5* The image at 1 month after MWA;

the exudate has disappeared. *6* The image at 3 months after MWA; an irregular cavity has been formed. *7* The image at 6 months after ablation; the tumor has shrunken. *8* The image at 9 months after ablation; the tumor has already shrunken and fibrosis has developed. *9* The image at 12 months after ablation; a fibrotic scar has developed. *10* The image at 24 months after ablation; the fibrotic scar has shrunken




Fig. 2 Kaplan-Meier plot of progression-free survival times




Fig. 3 Kaplan-Meier plot of overall survival times

factors are often unchangeable. Recently, an increasing number of studies have focused on the second factor. Radiotherapy and percutaneous thermal ablation are deemed as the most powerful therapies for achieving local tumor control. Several studies have explored radiotherapy for primary tumor sites in NSCLC patients. Although the optimal radiotherapy dose remains uncertain, there is no

doubt that it can improve the local control rate, palliate the symptoms of the disease, and improve survival. This benefit is mainly restricted to patients with good performance status and those with metastatic NSCLC or oligometastatic NSCLC tumors of limited volume [18–21]. However, long treatment times, radiation damage to normal tissues, and the high cost involved limits the application of radiotherapy.

As an alternative to radical surgery, thermal ablation has been used to treat early-stage patients in the past decade [11–13, 22–25]. Multiple studies have verified MWA as a simple, efficient, and safe cancer treatment modality. MWA administered to early-stage NSCLC patients has achieved complete ablation in 95–100 % of patients. Adverse events were observed in 47 % of patients. The median time to recurrence at ablative sites was  $16.2 \pm 1.3$  months. One-year, 2-year, and 3-year survival rates were 65, 55, and 45 %, respectively [11–13].

In the present study, a partial response to MWA was observed in 33 (84.6 %) patients, which was lower than reported in previous studies [11–13]. We consider that two factors resulted in this significant difference. First was the MWA dose and mean treatment time, which were 60–70 W and 6.7 min, respectively; however, in a previous study they were 70–80 W and 7–12 min, respectively. Second was the type of patient enrolled in the study; in our study, they were primary NSCLC patients, but in previous studies some had metastatic lung malignancy.

We explored the efficacy of MWA in combination with chemotherapy in advanced NSCLC patients. The ORR was 28.2 % and the DCR was 74.4 %. The ORR was similar to that reported in previous studies involving first-line doublet platinum-based chemotherapy in advanced NSCLC patients. However, the DCR in our study was superior to that reported in previous studies.

We also attempted to determine whether MWA in combination with first-line platinum-based chemotherapy could improve survival. The median PFS of enrolled patients was 8.7 months. In previous studies the median PFS in the Chinese population treated with platinum-based doublet chemotherapy was reported to range from 4.6 to 6.8 months [7, 26]. The combination of MWA and chemotherapy seemed to improve the PFS dramatically. To date, there have been no reports regarding the efficacy of MWA combined with chemotherapy in the treatment of advanced NSCLC. Several studies concerning the combination of radiofrequency ablation and chemotherapy in advanced NSCLC have shown that this approach could improve OS compared with chemotherapy alone; the median OS time ranged from 16.8 to 42 months [27–29]. In the current study the median OS time was 21.3 months, which was similar to that reported in previous studies. We suppose that the improved PFS was mainly due to the

decrease in tumor burden and the synergistic interaction between MWA and chemotherapy. Lee et al. [30] verified that 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging could be used to assess the prognostic value of tumor burden. An increase in total metabolic tumor volume (MTV) was associated with increased risk of progression and death [31]. For nonsurgical NSCLC patients, MTV, total lesion glycolysis and the standardized uptake value could be used as prognostic factors for OS independent of clinical stage [32]. Moreover, the Ki-67 level in the ablative sites could be utilized as an independent predictive factor regarding survival [33]. When NSCLC was treated using MWA, pathological analysis showed the formation of necrosis in the ablative zones [34, 35], and PET scans revealed no residual FDG activity in the ablated tumor sites [36]. Furthermore, tumor ablation will increase the level of interleukin (IL)-6 and IL-10; IL-6 promotes the progression of tumors. However, subsequent chemotherapy will inhibit tumor progression [37]. The decrease in tumor burden and the synergistic interaction between MWA and chemotherapy lead to the survival benefits.

Complications were observed in 22 (56.4 %) patients, which was a higher number than reported in previous studies involving early-stage lung cancer [11–13]; perhaps the baseline pulmonary disease and the advanced disease stage of patients resulted in this difference. However, serious adverse events were observed with a frequency of only 13.6 %. Consequently, the overall toxicity was tolerable. Considered overall, advanced NSCLC patients could benefit from MWA in combination with chemotherapy.

**Acknowledgments** The authors thank Hui Wang and Jian Zhu for medical writing assistance.

**Conflict of interest** Zhigang Wei, Xin Ye, Xia Yang, Aimin Zheng, Guanghui Huang, Xiang Ni, Wenhong Li, Jiao Wang, and Xiaoying Han have no conflicts of interest or financial disclosures to report.

## References

- Ahmedin J, Freddie B, Melissa M (2011) Global cancer statistics. *CA Cancer J Clin* 61:69–90
- Jemal A, Murray T, Ward E et al (2005) Cancer statistics. *CA Cancer J Clin* 55:10–30
- Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 361:947–957
- Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med* 361:958–967
- Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 362:2380–2388
- Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 11:121–128
- Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol* 12:735–742
- Takahashi T, Sonobe M, Kobayashi M et al (2010) Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. *Ann Surg Oncol* 17:889–897
- Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 363(18):1693–1703
- Furukawa K, Miura T, Kato Y et al (2005) Microwave coagulation therapy in canine peripheral lung tissue. *J Surg Res* 123:245–250
- Wolf FJ, Grand DJ, Machan JT et al (2008) Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. *Radiology* 247:871–879
- Abbas G, Pennathur A, Landreneau RJ et al (2009) Radiofrequency and microwave ablation of lung tumors. *J Surg Oncol* 100:645–650
- He W, Hu XD, Wu DF et al (2006) Ultrasonography-guided percutaneous microwave ablation of peripheral lung cancer. *Clin Imaging* 30:234–241
- Cliff, Philipp, Robin et al. (2005) The efficacy of preemptive analgesia for acute postoperative pain management: a meta-analysis. *Anesth Analg* 100: 757–773
- Goldberg SN, Grassi CJ, Cardella JF et al (2005) Image-guided tumor ablation: standardization of terminology and reporting criteria. *Radiology* 235:728–739
- Herrera LJ, Fernando HC, Perry Y et al (2003) Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. *J Thorac Cardiovasc Surg* 125(4):929–937
- Watanabe H, Okada M, Kaji Y et al (2009) New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1). *Gan To Kagaku Ryoho* 36:2495–2501
- Hasselle MD, Haraf DJ, Rusthoven KE et al (2012) Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. *J Thorac Oncol* 7:376–381
- Reinfuss M, Mucha-Malecka A, Walasek T et al (2011) Palliative thoracic radiotherapy in non-small cell lung cancer. An analysis of 1250 patients. Palliation of symptoms, tolerance and toxicity. *Lung Cancer* 71:344–349
- Bezjak A, Dixon P, Brundage M et al (2002) Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). *Int J Radiat Oncol Biol Phys* 54:719–728
- Nestle U, Nieder C, Walter K et al (2000) A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 Gy: results of a randomized equivalence study. *Int J Radiat Oncol Biol Phys* 48:95–103
- Simon CJ, Dupuy DE, DiPetrillo TA et al (2007) Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. *Radiology* 243:268–275
- Schneider T, Reuss D, Warth A et al (2011) The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms - results of an ablate and resect study. *Eur J Cardiothorac Surg* 39:968–973
- Lencioni R, Crocetti L, Cioni R et al (2008) Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). *Lancet Oncol* 9:621–628

25. Zemlyak A, Moore WH, Bilfinger TV (2010) Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer. *J Am Coll Surg* 211(1):68–72
26. Wu YL, Chu DT, Han B et al (2012) Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. *Asia Pac J Clin Oncol* 8(3):232–243
27. Wang SB, Chen JH, Cao WH et al (2005) The observation of the clinical effect for combination therapy of RFA with GP on advanced stage lung cancer. *Chinese J Clin Oncol* 32(11): 628–630
28. Lee H, Jin GY, Han YM et al (2012) Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. *Cardiovasc Intervent Radiol* 35:343–350
29. Zhang HM, Feng WJ, Zhou L et al (2008) Addition of cluster electrode radiofrequency ablation (RFA) to paclitaxel plus carboplatin (PC) for advanced NSCLC: clinical observation. *Eval Anal Drug-Use Hosp China* 8(7):540–542
30. Lee P, Weerasuriya DK, Lavori PW et al (2007) Metabolic tumor burden predicts for disease progression and death in lung cancer. *Int J Radiat Oncol Biol Phys* 69:328–333
31. Liao S, Penney BC, Wroblewski K et al (2012) Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. *Eur J Nucl Med Mol Imaging* 39:27–38
32. Scappaticci AA, Yoo DC (2012) Recurrence of lung cancer after radiofrequency ablation detected by PET/CT and contrast enhanced CT scan. *Med Health R I* 95:146–148
33. Sofocleous CT, Garg SK, Cohen P et al (2013) Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation. *Ann Surg Oncol* 20(Suppl 3):676–683
34. Clasen S, Krober SM, Kosan B et al (2008) Pathomorphologic evaluation of pulmonary radiofrequency ablation: proof of cell death is characterized by DNA fragmentation and apoptotic bodies. *Cancer* 113:3121–3129
35. Jaskolka JD, Kachura JR, Hwang DM et al (2010) Pathologic assessment of radiofrequency ablation of pulmonary metastases. *J Vasc Interv Radiol* 21:1689–1696
36. Ryan ER, Sofocleous CT, Schoder H et al (2013) Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. *Radiology* 268:288–295
37. Erinjeri JP, Thomas CT, Samoilia A et al (2013) Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. *J Vasc Interv Radiol* 24(8):1105–1112